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Abstract
Background: Whether nonsustained ventricular tachycardia (NSVT) is a marker of
increased risk of sustained ventricular tachyarrhythmias (VTAs) remains to be estab-
lished in patients receiving cardiac resynchronization therapy with a defibrillator
(CRT-D) for primary prevention.
Methods: Among the follow-up data of the Japan cardiac device treatment registry
(JCDTR) with an implantation date between January 2011 and August 2015, informa-
tion regarding a history of NSVT before the CRT-D implantation for primary preven-
tion had been registered in 269 patients. Outcomes were compared between two
groups with and without NSVT: NSVT group (n = 179) and No NSVT group (n = 90).
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Results: There was no significant difference with regard to age, gender, and NYHA
class between the two groups. Left ventricular ejection fraction (LVEF) was 25.6%
in the NSVT group and 28.0% in the No NSVT group (P = .046). The rate of appro-
priate therapy at 24 months was 26.0% and 18.4% in the NSVT and No NSVT
groups (P = .22), respectively. Survival free from heart failure death was reduced in
the NSVT group, as compared with the No NSVT group, with the rate of 90.2% vs
97.2% at 24 months (P = .030). A multivariate analysis identified a history of NSVT,
anemia, and no use of angiotensin-converting enzyme inhibitor (ACEI) or angioten-
sin-receptor blocker (ARB) as predictors of heart failure death.
Conclusions: NSVT appears to be a surrogate marker of severe heart failure rather
than a substrate for subsequent sustained VTAs in patients with CRT-D for primary
prevention.
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1 | INTRODUCTION
The significance of nonsustained ventricular tachycardia (NSVT) in
symptomatic heart failure patients had been evaluated in the late
1990s and early 2000s. In the Grupo de Estudio de la Sobrevida en
la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentri-
cos en Argentina (GESICA-GEMA) study, amiodarone reduced all-
cause mortality and sudden cardiac death in patients with severe
heart failure independently of the presence of NSVT, whereas NSVT
was an independent marker for increased rate of mortality and sud-
den cardiac death.1,2 The increased mortality associated with the
presence of NSVT was similar in the ischemic and nonischemic car-
diomyopathy.2 However, the Congestive Heart Failure-Survival Trial
of Antiarrhythmic Therapy (CHF-STAT) study showed that NSVT
had a trend as an independent predictor of all-cause mortality but
not for sudden death in patients with congestive heart failure and
ventricular arrhythmias.3 The Prospective Randomized Milrinone Sur-
vival Evaluation (PROMISE) study demonstrated that the presence of
NSVT was not a significant predictor of overall mortality or sudden
death in patients with moderate-to-severe heart failure (New York
Heart Association(NYHA) class III or IV) and a left ventricular ejec-
tion fraction (LVEF) of 35% or less.4 These studies were performed
before widespread use of beta-blocker, which can significantly
reduce sudden cardiac death. For example, the proportion of
patients taking beta-blockers was <10% in the CHF-STAT study and
0% in the PROMISE study. Therefore, the prognostic significance of
NSVT in patients with heart failure is ambiguous, and little is known
about the clinical implication of NSVT especially in patients receiving
contemporary care with guideline-directed medical therapy (GDMT)
including angiotensin-converting enzyme inhibitor (ACEI) or angio-
tensin-receptor blocker (ARB) and beta-blocker.
The aim of the present study is to evaluate the prognostic signif-
icance of NSVT and to examine the relationship between a history
of NSVT and implantable cardioverter–defibrillator (ICD) therapy in
heart failure patients receiving cardiac resynchronization therapy
with a defibrillator (CRT-D) for primary prevention based on data
from the Japan Cardiac Device Treatment Registry (JCDTR).
2 | METHODS
2.1 | Study population
The JCDTR was established in 2006 by the Japanese Heart Rhythm
Society (JHRS) for a survey of actual conditions in patients undergoing
implantation of cardiac implantable electronic devices (ICD/CRT-D/
CRT-P) as described previously.5-7 Members of the JHRS are encour-
aged to register their data under a unified protocol, which was nor-
mally approved by each facility. The protocol for this research project
has been approved by a suitably constituted Ethics Committee of the
institution and it conforms to the provisions of the Declaration of Hel-
sinki. In Hokkaido University Hospital, the protocol was approved on
September 20, 2012, by the Ethics Committee (approval number: 012-
0156). Among 2714 CRT-D recipients for primary prevention with an
implantation date between January 2011 and August 2015,8 the fol-
low-up data were available in 620 patients as of September 16, 2015.9
Information regarding presence or absence of NSVT had been regis-
tered at the CRT-D implantation in 269 patients (43%). These 269
patients were analyzed in the present study. NSVT was defined as 3 or
more consecutive beats arising below the atrioventricular node with a
rate of >100 beats/min and lasting <30 seconds.
2.2 | Outcomes
The analyzed events were (i) death from any cause, (ii) heart failure
death, (iii) sudden cardiac death, (iv) noncardiac death, and (v) appro-
priate and inappropriate ICD therapies including shock and/or
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antitachycardiac pacing. The diagnosis of the cause of death was
made by attending physicians.
2.3 | Statistical analysis
All data are expressed as mean  SD. Simple between-group analy-
sis was conducted using Student’s t-test. Categorical variables were
compared using Fisher’s exact test. Kaplan–Meier curves were con-
structed to estimate event-free outcomes in the two study groups
with comparison using the log-rank test. A multivariate Cox propor-
tional-hazards regression model was used to estimate hazard ratios
for clinical events. Among the variables that reached a significance
level of P < .1 in univariate models, a stepwise selection was used to
determine the most agreeable model. Differences with P < .05 were
considered significant. Statview version 5.0 for Windows (SAS
Institute Inc, Cary, NC, USA) or R software ver.3.2.3 (https://www.
r-project.org/) was used for all statistical analyses.
3 | RESULTS
3.1 | Patient characteristics
The characteristics of patients receiving CRT-D for primary preven-
tion with (n = 179; NSVT group) or without (n = 90; No NSVT
group) NSVT are shown in Table 1. These data were derived from
the status of each patient just before the implantation of CRT-D.
TABLE 1 Characteristics of the patients
NSVT (n = 179) No NSVT (n = 90) P value
Age (y) 64.9  12.1 66.1  11.0 .436
Male 141 (78.8) 64 (71.1) .164
Underlying heart disease
Ischemic 37 (20.7) 33 (36.7) .0048
Nonischemic 142 (79.3) 57 (63.3)
LVEF (%) 25.6  9.0 28.0  9.9 .046
LVEF ≦30% 134 (74.9) 62 (68.9) .299
NYHA class
I 1 (0.6) 3 (3.3) .267
II 44 (24.6) 26 (28.9)
III 117 (65.4) 53 (58.9)
IV 17 (9.5) 8 (8.9)
Heart rate (/min) 72.1  16.6 69.2  14.7 .162
QRS duration (ms) 149.0  32.7 152.9  27.9 .338
QT interval (ms) 445.8  53.4 454.2  52.7 .226
Atrial lead
Absent 29 (16.2) 9 (10.0) .168
Present 150 (83.8) 81 (90.0)
AF 26 (14.5) 12 (13.3) .791
Diabetes mellitus 45 (25.1) 31 (34.4) .110
Hypertension 64 (35.8) 44 (48.9) .038
Dyslipidemia 57 (31.8) 34 (37.8) .332
Hyperuricemia 34 (19.0) 18 (20.0) .844
Cerebral infarction 14 (7.8) 8 (8.9) .763
Peripheral artery disease 3 (1.7) 5 (5.6) .077
BNP (pg/mL)a 690.1  706.4 474.5  567.6 .017
Hemoglobin (g/dL) 13.2  1.9 12.8  1.9 .196
Creatinine (mg/dL) 1.28  0.99 1.41  1.69 .415
Goldenberg scoreb 2.2  1.1 2.3  1.1 .501
LVEF, left ventricular ejection fraction; AF, atrial fibrillation.
Values are means  SD, or number (%).
aThe value of BNP was missing in 15 patients with NSVT and 8 patients without NSVT.
bThe original risk score model comprised 5 clinical factors including (i) NYHA class > II, (ii) AF, (iii) QRS duration >120 ms, (iv) age >70 years, and (v)
blood urea nitrogen (BUN) >26 mg/dL. Because BUN was not collected in the JCDTR database, blood creatinine >1.5 mg/dL was used as a risk factor
instead of BUN.
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Proportion of nonischemic etiology was higher, and LVEF was lower
in patients with NSVT than in those without NSVT. Patients with
NSVT were less likely to have a history of hypertension. The level of
BNP was higher in the NSVT group, as compared with that in the
No NSVT group, although it was missing in about 10% of the
patients. The distribution of NYHA functional class was not signifi-
cantly different between the two groups.
Pharmacological therapy in the NSVT and No NSVT groups is
shown in Table 2. Use of aldosterone antagonists and oral anticoag-
ulant agents was higher in the NSVT group vs No NSVT group. The
rate of having antiplatelet agents was lower in the NSVT group than
in the No NSVT group.
3.2 | Outcomes
During a mean follow-up of 21  12 months, death from any cause
occurred in 40 of 179 patients (22.3%) in the NSVT group and 9 of
90 patients (10.0%) in the No NSVT group. These events included
21 heart failure deaths (11.7%) and 6 sudden cardiac death (3.3%) in
the NSVT group and 2 heart failure death (2.2%) and 2 sudden car-
diac death (2.2%) in the No NSVT group.
Kaplan–Meier estimates of event-free survival in the two groups
are shown in Figure 1. There was an increased trend in the risk of
death (P = .074) and a significant increase in the risk of heart failure
death (P = .030) in the NSVT group as compared with the No NSVT
group (Figure 1A,B). The rate of sudden cardiac death and noncar-
diac death did not differ between the two groups (Figure 1C,D).
With regard to the rate of appropriate and inappropriate ICD ther-
apy (shock and/or antitachycardiac pacing), there was no significant
difference between the two groups (Figure 2A,B).
The variables associated with the risk of heart failure death
obtained by univariate models (P < .1) were presence of NSVT
(P = .047), hemoglobin (P = .090), use of angiotensin-converting
enzyme inhibitor (ACEI) or angiotensin II-receptor blocker (ARB)
(P = .019), and use of aldosterone antagonists (P = .078). In this
selected population, LVEF was not significantly associated with a risk
of heart failure death by a univariate analysis (hazard ratio 0.96;
95% confidence interval [CI], 0.91 to 1.01; P = .124) and it was not
included in the multivariate analysis. A stepwise regression modeling
was used to identify factors associated with heart failure death. They
were presence of NSVT, hemoglobin, and use of angiotensin-con-
verting enzyme inhibitor (ACEI) or angiotensin II-receptor blocker
(ARB), and hazard ratios determined by a multivariate Cox propor-
tional-hazards regression model are shown in Figure 3.
4 | DISCUSSION
The present study demonstrated, with analyses of the JCDTR data-
base, a history of NSVT was associated with increased risk of heart
failure death in patients undergoing a CRT-D implantation, whereas it
was not a significant predictor of subsequent appropriate ICD thera-
pies. In addition to NSVT, no use of ACEI/ARB and the lower level of
hemoglobin were identified as predictors of heart failure death. It is
important to adhere to the current GDMT, especially ACEI/ARB for
reducing the mortality in heart failure patients receiving CRT-D.
CRT reduces mortality similarly in both ischemic and nonischemic
cardiomyopathy, whereas a defibrillator function could prolong the
long-term survival, especially of CRT recipients with an ischemic eti-
ology for primary prevention of sudden cardiac death.10 In a previous
analysis of the JCDTR database, we identified four factors associated
with CRT-D vs CRT-P implantation in heart failure patients without
sustained ventricular tachyarrhythmias.8 They were male gender,
younger age, reduced LVEF, and a history of NSVT. In contrast to the
COMPANION11 and REVERSE12 studies, no significant superiority of
CRT-D to CRT-P, in terms of reducing the risk of death, was
observed in a recent study of the JCDTR after adjusting the clinical
variables.9 This may be in part due to an incomplete adjustment of
the study populations. For example, information regarding presence
or absence of NSVT was missing in about 60% of the patients,
thereby excluding it as a variable for the multivariate analysis.9
The observation that the rate of appropriate ICD therapies was
not significantly higher in CRT-D recipients with NSVT than in those
without NSVT is not surprising, as most of the studies in heart failure
patients reported that NSVT did not specifically predict sudden car-
diac death or major arrhythmic events of sustained VT/VF and that
low LVEF was the predictor of these events (Table 3).3,4,13 One of
the important findings is that NSVT in patients with reduced LVEF
represented the higher risk of heart failure death despite the pres-
ence of CRT and beta-blocker therapy with a rate of more than 70%.
This is in agreement that nonischemic CRT-D recipients with NSVT
in the MADIT-CRT study had an increased risk of the combined end
point of heart failure and death, as compared with those without
TABLE 2 Pharmacological therapy
NSVT
(n = 179)
No NSVT
(n = 90) P value
Ia 1 (0.6) 1 (1.1) .619
Ib 2 (1.1) 1 (1.1) .996
Ic 0 (0.0) 1 (1.1) .158
b-blockers 141 (78.8) 63 (70.0) .113
III 67 (37.4) 26 (28.9) .165
Ca2+ antagonists 12 (6.7) 6 (6.7) .991
Digitalis 24 (13.4) 10 (11.1) .593
Diuretics 147 (82.1) 66 (73.3) .094
ACEI/ARB 125 (69.8) 67 (74.4) .430
Aldosterone antagonists 93 (52.0) 34 (37.8) .028
Nitrates 24 (13.4) 10 (11.1) .593
Statins 53 (29.6) 37 (41.1) .059
Oral anticoagulant agents 99 (55.3) 36 (40.0) .018
Antiplatelet agents 58 (32.4) 43 (47.8) .014
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II-recep-
tor blocker.
Data are given as number (%).
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NSVT.14 Moreover, in the study population of Sudden Cardiac Death
in Heart Failure Trial (SCD-HeFT), rapid-rate NSVT identified in the
ICD log was associated with a >4-fold higher risk of a subsequent
first appropriate shock and a >2-fold higher risk of death compared
with patients without NSVT.15 MADIT-CRT patients with NSVT had
a higher burden of premature ventricular contractions (PVCs), lower
percentage of biventricular pacing, and less reverse remodeling.14
These findings may explain the worse outcomes of CRT-D patients
with NSVT, implicating the potential therapeutic interventions for the
management of NSVT and PVCs in heart failure patients.
NSVT beyond 24-48 hours after acute myocardial infarction and/
or acute coronary syndrome is associated with the risk of cardiovas-
cular death (Table 4),16-18 especially during the first 30 days after
presentation.16 The MERLIN-TIMI 36 study reported an interesting
relationship between the rate of sudden cardiac death and the num-
ber of beats during NSVT for the first 7 days of non-ST elevation
acute coronary syndrome (Table 4).18 In the DINAMIT19 and IRIS20
studies, prophylactic ICD therapy reduced arrhythmic and sudden
cardiac death, but it did not reduce overall mortality in patients with
a reduced LVEF (≦40% or ≦35%) and <40 days after a myocardial
infarction. One of the enrollment criteria for the IRIS study was to
detect NSVT on days 5-31 after infarction. Those studies concluded
that the factors associated with arrhythmia requiring ICD therapy are
also associated with an increased risk of nonsudden death.19-21
Therefore, it is reasonable to consider that NSVT in patients with a
reduced LVEF represents a sign of severe failing hearts.
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F IGURE 1 Kaplan–Meier estimates for event-free survival in CRT-D recipients for primary prevention of sudden cardiac death with and
without prior history of NSVT. Outcome events were death from any cause (A), heart failure death (B), sudden cardiac death (C), and
noncardiac death (D). The mean follow-up period was 22  12 months in the NSVT group and 19  11 months in the No NSVT group
(P = .078). A, The rate of death from any cause at 12 and 24 months was 12.8% and 19.8% in the NSVT group, and 7.1% and 12.1% in the
No NSVT group (NSVT vs No NSVT, P = .074 by log-rank test). B, The rate of heart failure death at 12 and 24 months was 5.2% and 9.8% in
the NSVT group, and 2.8% and 2.8% in the No NSVT group (NSVT vs No NSVT, P = .030 by log-rank test). C, The rate of sudden cardiac
death at 12 and 24 months was 3.1% and 3.9% in the NSVT group, and 1.2% and 3.0% in the No NSVT group (NSVT vs No NSVT, P = .655
by log-rank test). D, The rate of noncardiac death at 12 and 24 months was 4.4% and 7.5% in the NSVT group, and 3.3% and 6.8% in the No
NSVT group (NSVT vs No NSVT, P = .829 by log-rank test)
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Risk stratification of sudden cardiac death remains to be estab-
lished among patients with relatively preserved LVEF (>40%).
Although the risk of sudden cardiac arrest was low (0.35% per year) in
this population with preserved LVEF of >50%,22 the absolute number
of the victims was highest in the preserved LVEF category.22,23 It is
interesting that NSVT was a predictor of sudden cardiac death in
patients after acute myocardial infarction only when LVEF was
>35%.24 Similarly, in nonischemic dilated cardiomyopathy after opti-
mization of medical treatment, NSVT was associated with a higher risk
of major ventricular arrhythmias if LVEF was >35%, but not if LVEF
was ≦35%.25 NSVT in combination with other noninvasive evalua-
tions, such as late gadolinium enhancement,26 periodic repolarization
dynamics,27 and multiple 12-lead ECG parameters,28 might identify
patients at risk of sudden cardiac death with preserved LVEF.
The second version of JCDTR is now under construction in the
ICD Committee of the Japanese Heart Rhythm Society (JHRS), and it
will be updated within a year. With voluntary efforts by members of
the JHRS, we hope the next generation of JCDTR will be able to
provide firm and further evidence of Japanese patients.
4.1 | Study limitations
There are several limitations to be considered in this study. First, it
is not known how and when the history of NSVT in each patient
was determined. Occurrence of NSVT depends on the duration of
ECG recording time and the clinical setting. For example, NSVT iden-
tified in hospital, compared with that identified out-of-hospital, was
associated with a higher risk of mortality.29 Second, the number of
events may have been small for adjusting the large number of clinical
variables for the proper multivariate regression analysis. Third, the
ICD programming was left on the discretion of each attending doc-
tor and appropriate ICD therapies included both shock and anti-
tachycardiac pacing. Programming of ICD therapies affect all-cause
mortality during long-term follow-up and is also associated with
occurrence appropriate antitachycardiac pacing.30 Fourth, informa-
tion with regard to the percent biventricular pacing is lacking in the
JCDTR database. The mortality benefit was associated with an
increasing percentage of biventricular pacing in CRT recipients.31
5 | CONCLUSIONS
The present study demonstrated that a history of NSVT in CRT-D
recipients for primary prevention enrolled in the JCDTR was associ-
ated with a higher risk of heart failure death, but with a similar rate
of appropriate ICD therapies, as compared with no prior history of
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F IGURE 2 Kaplan–Meier curves comparing first occurrence of
ICD therapy between CRT-D recipients for primary prevention of
sudden cardiac death with vs without prior history of NSVT. A, The
rate of appropriate ICD therapy at 12 and 24 months was 15.1%
and 26.0% in the NSVT group, and 10.6% and 18.4% in the No
NSVT group (NSVT vs No NSVT, P = .229 by log-rank test). B, The
rate of inappropriate ICD therapy at 12 and 24 months was 5.7%
and 7.3% in the NSVT group, and 6.0% and 7.8% in the No NSVT
group (NSVT vs No NSVT, P = .357 by log-rank test)
F IGURE 3 Hazard ratio for heart failure death determined by a
stepwise Cox regression for possible factors in CRT-D recipients for
primary prevention of sudden cardiac death. The presence of NSVT
(hazard ratio with NSVT vs without NSVT, 4.73; 95% confidence
interval [CI], 1.09 to 20.43; P = .037), lower hemoglobin level
(hazard ratio per unit (g/dl) hemoglobin, 0.77; 95% CI, 0.60 to 0.99;
P = .038), and no use of angiotensin-converting enzyme inhibitor
(ACEI) or angiotensin II-receptor blocker (ARB) (hazard ratio with
ACEI/ARB vs without ACEI/ARB, 0.37; 95% CI, 0.16 to 0.85;
P = .019) were significantly associated with heart failure death in
CRT-D recipients for primary prevention
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TABLE 3 Prognostic significance of NSVT in patients with heart failure
Incidence
of NSVT Isch NYHA class LVEF NSVT in heart failure
GESICA-GEMA (1996)
(n = 516)2
34% 38% II 20% ≤35% RR for death 1.69; 95%CI 1.27-2.24, P < .0002
RR for SD 2.77; 95% CI 1.78-4.44, P < .001III 48%
IV 32%
CHF STAT (1998) (n = 674)3 78% 70% II 55% ≤40% NSVT showed a trend (P = .07) as a predictor for mortality but not for SD
III, IV 45%
PROMISE (2000) (n = 1080)4 61% 54% III 58% ≤35% NSVT did not specifically predict SD
IV 42% EF was the most powerful predictor of SD
MACAS (2003) (n = 343)13 32% 0% I 12% ≤45% RR of NSVT for MAEs 1.71; 95%CI 0.88-3.31, P = .106
II 63% RR of EFa for MAEs 2.28; 95%CI 1.55-3.33, P = .0001
III 25% RR of betab for MAEs 0.59; 95%CI 0.29-1.19, P = .134
N, number of patients; Isch, ischemic cardiomyopathy; RR, relative risk; 95%CI, 95% confidence interval; SD, sudden death; MAEs, major arrhythmic
events defined as sustained VT, VF or sudden death; GESICA-GEMA, Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina
(GESICA) -Grupo de Estudios Multicentricos en Argentina (GEMA); CHF-STAT, Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy; PRO-
MISE, Prospective Randomized Milrinone Survival Evaluation; MACAS, Marburg Cardiomyopathy Study.
a10% decrease of LVEF.
bbeta: beta-blockers.
TABLE 4 Prognostic significance of NSVT in patients after myocardial infarction and acute coronary syndrome
Study (year)
F/U
(mo)
Incidence
of NSVT Post-MI
Age
(y)
LVEF
(%) Mortality or others
Bigger et al (1984) (n = 766)32 22 11% LVEF <30% vs LVEF ≧30%, HR 3.5, P < .001
NSVT vs No NSVT, HR 1.9, P < .05
Cheema et al (1998) (n = 224)17 34 72 h 65 49% NSVT ≦24 h had no risk
64 50% NSVT >24 h had poor survival, P < .0001
Hohnloser et al (1999) (n = 325)33 30 9% 10 d 58 49 No predictive value of NSVT for SCD or AEs
Buxton et al (2000) (n = 1750)34 39 >4 d 67 ≦40% NSVT with vs without inducible VT during EPS
HR 1.3, P = .005
HR for SCD or CA 1.5, P < .001
La Rovere et al (2001) (n = 1071)35 21 13% 30 d 59 49 NSVT, RR for CD 3.1, P < .001
LVEF <35% & NSVT, RR for AEs 9.0, P < .001
Makikallio et al (2005) (n = 2130)24 34 AMI 59 NSVT in pts with an EF >35%, HR for SCD 3.5, P < .001
NSVT in pts with an EF ≦35%, HR for SCD NS
Huikuri et al (2009) (n = 312)36 24 13% 5-21 d & 6 wk 65 ≦40%
(31%)
No predictive value of NSVT for fatal or near-fatal AEs
Scirica et al (2010) (n = 6345)18,a 12 57%b 3-7 d 63 NSVT 3 beats, HR for SCD 1.1, P = .74, 1.4%/y
NSVT 4-7 beats, HR for SCD 2.3, P < .001, 2.9%/y
NSVT ≧8 beats, HR for SCD 2.8, P = .001, 4.3%/y
Bui et al (2016) (n = 2866)16,c 9 36% & 22%d 0-7 d & 30 d 63 NSVT ≦48 h had no risk of CD
NSVT >48 h, HR for CD 1.87, P = .02
NSVT at 30 d showed an increased risk of CD for an
additional several months
N, number of patients; F/U, follow-up period; mo, months; d, day; wk, week; y, year; MI, myocardial infarction; AMI, acute MI; LVEF, left ventricular
ejection fraction; HR, hazard ratio; RR, relative risk; SCD, sudden cardiac death; AEs, arrhythmic events; pts, patients; NS, not significant; CD, cardiac
death; EPS, electrophysiological study; CA, cardiac arrest.
aPatients with non-ST-elevation acute coronary syndrome (NSTEACS) were enrolled.
bContinuous ECG monitoring was performed with the median time of 6.0 days.
cPatients with acute coronary syndrome (ACS) were enrolled.
dContinuous ECG monitoring was performed for ≦7 days.
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NSVT. NSVT in heart failure patients appears to indicate a sign of a
more severe failing heart rather than a substrate for subsequent sus-
tained VTAs even in the presence of CRT.
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